Medicines and Healthcare products Regulatory Agency

🚨 We've approved semaglutide (Wegovy) to reduce risk of serious heart problems in obese or overweight adults This medicine, a GLP-1 receptor agonist, was already approved for use in the treatment of obesity and for weight management, to be used alongside diet, physical activity and behavioural support. The approval means that semaglutide is the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Our Deputy Director of Innovative Medicines, Shirley Hopper, said: "Our key priority is enabling access to high quality, safe and effective medical products. “We’re assured that the appropriate regulatory standards of safety, quality and effectiveness for the approval of this medicine have been met. This treatment option that prevents heart disease and strokes is an important step forward in tackling the serious health consequences of obesity. “As with all medicines, we will keep its safety under close review.’’ Find out more ➡️ https://bit.ly/4fiWJGP

🛎️The Commission on Human Medicines (CHM) is looking to appoint a General Practitioner to the Paediatric Medicines Expert Advisory Group (PM EAG)🛎️ The PM EAG is an independent advisory committee of the CHM that provides impartial advice to Ministers on matters relating to the regulation of medicines used for paediatric use, including all matters relating to the implementation of the Paediatric Regulation. The CHM advises ministers on the safety, efficacy and quality of medicinal products. CHM is an advisory non-departmental public body, sponsored by the Department of Health and Social Care. The Medicines and Healthcare products Regulatory Agency provides administrative support to the CHM. To find out more about this role and to apply, visit 🔗 https://bit.ly/3KgTpxb 📌 The closing date for applications is 05 August 2024

📢 We've approved the first generic raltegravir medicines to treat adult and paediatric patients infected by HIV Raltegravir works by stopping HIV-produced enzyme HIV integrase (which enables multiplication of the virus in cells within the body) from working. When used with other medicines, it may reduce the amount of HIV in the patient’s blood and increase the patient’s CD4-cell count (a type of white blood cell that plays an important role in maintaining a healthy immune system). Reducing the amount of HIV in the blood may improve the functioning of the immune system, meaning the body may fight infection better. Our Deputy Director of Innovative Medicines, Shirley Hopper, said: "Ensuring timely access to generic medicines is a key priority for us. “Appropriate data have been provided to assure us that these medicines are the same as, and considered interchangeable with an already licensed reference medicine, called Isentress. “As with all products, we will keep the safety of raltegravir under close review.’’ Find out more ➡️ https://bit.ly/3LxQJwc

🔍 We’re looking for a Data Protection Lead in our Digital and Technology Group (D&T) 🔍 The Digital and Technology Group (D&T) is responsible for making sure that our scientists, inspectors and all of our staff have the tools and data they need to deliver the very best services they can to improve outcomes for patients and the general public. The Data Protection Lead will be responsible for championing data protection across the Agency by supporting the maintenance and enhancement of our existing services - leading the development of new services and approaches that will improve data protection practice in the Agency. 📌 Applications close 2 August 2024 To learn more about the role, and to apply visit ➡️ https://bit.ly/46cASg0

🛎️The Commission on Human Medicines (CHM) is looking to appoint a haematologist with expertise in haematological oncology to the Oncology and Haematology Expert Advisory Group (OHEAG)🛎️ The CHM is looking for an experienced clinician practising in academic institutions, tertiary hospitals or large district hospitals, with experience in complex clinical scenarios and academic work including clinical trials. The CHM advises ministers on the safety, efficacy and quality of medicinal products. CHM is an advisory non-departmental public body, sponsored by the Department of Health and Social Care. The Medicines and Healthcare products Regulatory Agency provides administrative support to the CHM. To find out more about this role and to apply, visit 🔗 https://bit.ly/3KgTpxb 📌 The closing date for applications is 29 July 2024

📢 Our Clinical Practice Research Datalink (CPRD) team is looking for a Research Manager in the Safety and Surveillance group 📢 To learn more about the role and to apply, visit ➡️ https://bit.ly/4euEpKF

📢 Our Clinical Practice Research Datalink (CPRD) team is looking for a Clinical Study Development Manager in the Safety and Surveillance group 📢 To learn more about the role and to apply, visit ➡️https://bit.ly/3WhyVvN

🛎️The Commission on Human Medicines (CHM) is looking to appoint a General Practitioner to the Paediatric Medicines Expert Advisory Group (PM EAG)🛎️ The PM EAG is an independent advisory committee of the CHM that provides impartial advice to Ministers on matters relating to the regulation of medicines used for paediatric use, including all matters relating to the implementation of the Paediatric Regulation. The CHM advises ministers on the safety, efficacy and quality of medicinal products. CHM is an advisory non-departmental public body, sponsored by the Department of Health and Social Care. The Medicines and Healthcare products Regulatory Agency provides administrative support to the CHM. To find out more about this role and to apply, visit 🔗 https://bit.ly/3KgTpxb 📌 The closing date for applications is 22 July 2024

📢 Our Clinical Practice Research Datalink (CPRD) team is looking for an Operations Coordinator in the Safety and Surveillance group 📢 To learn more about the role and to apply, visit ➡️ https://bit.ly/3z8oiSN

📢Our Clinical Practice Research Datalink (CPRD) team is looking for Data Engineers (Real World Data) to join our CPRD team in the Safety and Surveillance group📢 To learn more about the role and to apply, visit ➡️ https://bit.ly/4eq2G4o